Sugi Predict

Sugi Predict / Compounds / SCHEMBL3982583

SCHEMBL3982583

SCHEMBL3982583

O=S(=O)(OCCc1cccs1)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ TAAR1 Q96RJ0 1/20 0.42
▸ ALDH1A1 P00352 3/20 0.40
▸ TSHR P16473 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ POLB P06746 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ ATM Q13315 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ HPGD P15428 2/20 0.39
▸ TTK P33981 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ CA9 Q16790 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1418052 0.86 MEN1 (0.46) ALDH1A1TSHRSMN1; SMN2POLBL3MBTL1
SCHEMBL13316992 0.84 ALDH1A1 (0.39) TAAR1ALDH1A1TSHRSMN1; SMN2POLB
SCHEMBL13298070 0.83 THRB (0.46) ALDH1A1SMN1; SMN2POLBL3MBTL1HTT
SCHEMBL1682780 0.79 L3MBTL1 (0.44) TAAR1ALDH1A1TSHRSMN1; SMN2POLB
SCHEMBL1161703 0.78 TAAR1 (0.46) TAAR1ALDH1A1TSHRSMN1; SMN2POLB
SCHEMBL29003425 0.78 TAAR1 (0.46) TAAR1ALDH1A1TSHRSMN1; SMN2POLB
SCHEMBL3449015 0.76 PARL (0.50) ALDH1A1TSHRSMN1; SMN2L3MBTL1HPGD
SCHEMBL1989355 0.76 KMT2A (0.46) ALDH1A1L3MBTL1HTTNPC1HPGD
SCHEMBL2476597 0.75 CA1 (0.63) ALDH1A1TSHRCA1CA2CA9
SCHEMBL25061946 0.74 NPC1 (0.49) ALDH1A1TSHRSMN1; SMN2POLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2585428-B1 PROCESSES FOR THE RESOLUTION OF NITROGEN SUBSTITUTED (S)-5-ALKOXY-2-AMINOTETRALIN DERIVATIVES UCB BIOPHARMA SPRL (BE) 2017-05-10 — — EP claimed
US-8981121-B2 Process for the preparation of nitrogen substituted aminotetralins derivatives UCB PHARMA GMBH (DE) 2015-03-17 — — US claimed
EP-2585428-A2 PROCESSES FOR THE RESOLUTION OF NITROGEN SUBSTITUTED (S)-5-ALKOXY-2-AMINOTETRALIN DERIVATIVES UCB Pharma GmbH (DE) 2013-05-01 — — EP claimed
US-20130102794-A1 Novel Process for the Preparation of Nitrogen Substituted Aminotetralins Derivatives UCB PHARMA GMBH (DE) 2013-04-25 — — US claimed
CN-101519401-B Intermediate (S)-2-(2-thiophene ethylamine)(2-chlorphenyl)methyl acetate of clopidogrel and method for preparing salts thereof SHANGHAI ECUST BIOMEDICINE CO LTD 2012-12-05 — — CN claimed
WO-2011161255-A2 NOVEL PROCESS FOR THE PREPARATION OF NITROGEN SUBSTITUTED AMINOTETRALINS DERIVATIVES UCB PHARMA GMBH (DE) 2011-12-29 — — WO claimed
CN-101519401-A Intermediate (S)-2-(2-thiophene ethylamine)(2-chlorphenyl)methyl acetate of clopidogrel and method for preparing salts thereof SHANGHAI ECUST BIOMEDICINE CO 2009-09-02 — — CN claimed
EP-1232152-B1 IMPROVED PROCESS FOR PREPARING NITROGEN-SUBSTITUTED AMINOTETRALINS ADERIS PHARMACEUTICALS INC (US) 2004-02-04 — — EP claimed
EP-1232152-A1 IMPROVED PROCESS FOR PREPARING NITROGEN-SUBSTITUTED AMINOTETRALINS Aderis Pharmaceuticals, Inc. (US) 2002-08-21 — — EP claimed
US-6372920-B1 ALKYLATING 2-AMINOTETRALIN IN PRESENCE OF BASE SELECTED FROM ALKALI METAL CARBONATES AND BICARBONATES, WHEREIN AMOUNT OF BASE IS LESS THAN ABOUT 1.9-FOLD MOLAR EXCESS WITH RESPECT TO AMOUNT OF 2-AMINOTETRALIN ADERIS PHARMACEUTICALS, INC. 2002-04-16 — — US claimed
WO-2001038321-A1 IMPROVED PROCESS FOR PREPARING NITROGEN-SUBSTITUTED AMINOTETRALINS ADERIS PHARMACEUTICALS, INC. (US) 2001-05-31 — — WO claimed
CN-119745876-A Application of clopidogrel in preparation of medicines for preventing renal ischemia reperfusion injury 中国人民解放军陆军军医大学第一附属医院 2025-04-04 — — CN disclosed
EP-2585428-B1 PROCESSES FOR THE RESOLUTION OF NITROGEN SUBSTITUTED (S)-5-ALKOXY-2-AMINOTETRALIN DERIVATIVES UCB BIOPHARMA SPRL (BE) 2017-05-10 — — EP disclosed
US-8981121-B2 Process for the preparation of nitrogen substituted aminotetralins derivatives UCB PHARMA GMBH (DE) 2015-03-17 — — US disclosed
EP-2585428-A2 PROCESSES FOR THE RESOLUTION OF NITROGEN SUBSTITUTED (S)-5-ALKOXY-2-AMINOTETRALIN DERIVATIVES UCB Pharma GmbH (DE) 2013-05-01 — — EP disclosed
US-5191090-A Preparation of 2-(2'-thienyl)ethylamine derivatives and synthesis of thieno[3,2-c]pyridine derivatives therefrom SYNTEX (U.S.A.) INC. (US) 1993-03-02 — — US disclosed
US-5068360-A Preparation of 2-(2'-thienyl)ethylamine derivatives and synthesis of thieno(3,2-C)pyridine derivatives therefrom SYNTEX (U.S.A.) INC. (US) 1991-11-26 — — US disclosed
EP-0439404-A2 Preparation of 2-(2'-thienyl) alkylamines and derivatives thereof and synthesis of 4,5,6,7- thieno [3,2-c] pyridine derivatives therefrom SANOFI (FR) 1991-07-31 — — EP disclosed
US-4997945-A Ticlopidine intermediate SYNTEX (U.S.A.) INC. (US) 1991-03-05 — — US disclosed
US-4873343-A Process for the preparation of N-(2-chlorobenzyl)-2-(2-thienyl) ethylamine SANOFI (FR) 1989-10-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130102794-A1 Novel Process for the Preparation of Nitrogen Substituted Aminotetralins Derivatives AANAT, AADAT, ASNS TAAR1 99/4885ALDH1A1 1552/4885TSHR 1810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.